“New doesn’t mean better”: towards a new concept of innovative health technology
DOI:
https://doi.org/10.35434/rcmhnaaa.2022.15Supl.%201.1532Keywords:
inventions, innovation, Technology Assessment, Biomedical, Technology , Biomedical TechnologyAbstract
An innovative health technology (IHT) should be understood as a new technology that is better in its benefits than the status quo in the local health system. The additional benefit that the IHT means must refer to relevant outcomes for a society based on complete best quality scientific evidence. This proposed definition of IHT then highlights the social value of a health technology, which can be made explicit through that methodological tool, increasingly used globally, called health technology assessment. This approach can help governments, from an ethical and economic perspective, to ensure a more efficient distribution of resources and public budgets for rapid and equitable access of the population to IHT. This article proposes and supports the implementation of this definition of IHT in the decision-making processes in health in the Peruvian context.
Downloads
Metrics
References
Wieseler B, McGauran N, Kaiser T. New drugs: where did we go wrong and what can we do better?. BMJ. 2019;l4340. Doi: 10.1136/bmj.l4340
Lenzer J, Brownlee S. Should regulatory authorities approve drugs based on surrogate endpoints?. BMJ. 2021;374:n2059. doi: 10.1136/bmj.n2059
Dawoud D, Naci H, Ciani O, Bujkiewicz S. Raising the bar for using surrogate endpoints in drug regulation and health technology assessment. BMJ. 2021;374:n2191. doi: 10.1136/bmj.n2191
The BMJ. Surrogate endpoints need complementary patient reported outcomes [Internet]. BMJ; 2021[citado el 30 de octubre de 2021]. Available from: https://bit.ly/3EeJpBw
Rivera PA, Rodríguez-Zúñiga MJM, Caballero-Alvarado J, Fiestas F. Glycated hemoglobin as a surrogate for evaluating the effectiveness of drugs in diabetes mellitus trials: a systematic review and trial-level meta-analysis. Int J Technol Assess Health Care [Internet]. 2022 [citado el 26 de mayo de 2022];38(1):e12. Disponible en: https://bit.ly/3RS66Rj
IQWIG. Validity of surrogate endpoints in oncology [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care; 2011 [citado el 10 de septiembre de 2022]. Available from: https://bit.ly/3g390Wp
EUnetHTA. Endpoints used for relative effectiveness assessment of pharmaceuticals [Internet]. European network for Health Technology Assessment ;2013 [citado el 26 de mayo de 2022]. Disponible en: https://bit.ly/3UDTsqR
NICE Decision Support Unit. The value of innovation report by the decision support unit [Internet]. NICE; 2009 [citado el 6 de abril de 2022]. Disponible en: https://bit.ly/3TUEPyx
Kennedy I. Appraising the value of innovation and other benefits: a short study for nice [Internet]. NICE; 2009 [citado el 6 de abril de 2022]. Disponible en: https://bit.ly/3EeeDsL
NICE. Report to the Methods Review Working Party Key issues arising from workshop on structured decision making [Internet]. NICE; 2012 [citado el 6 de abril de 2022]. Disponible en: https://bit.ly/3hH7ucO
NICE. Guide to the methods of Technology appraisal 2013 [Internet]. NICE; 2013 [citado el 20 de Mayo de 2022]. Disponible en: https://bit.ly/3X8D4jK
Biblioteca Nacional de Medicina de Estados Unidos. Inventions - MeSH - NCBI [Internet]. 2021 [citado el 27 de octubre de 2021]. Disponible en: https://bit.ly/3AixMZl
Biblioteca Virtual en Salud. DeCS Server - Hierarchic: Innovación [Internet]. 2021 [citado el 20 de octubre de 2021]. Disponible en: https://bit.ly/3xcfsPS
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Elmer Fiestas, Dr. Víctor Dongo, Dr. Fabián Fiestas
This work is licensed under a Creative Commons Attribution 4.0 International License.